BIOGEN INC. Impairment of Long-Lived Assets Held-for-use
BIOGEN INC. (BIIB) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-10-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2013-10-28
- BIOGEN INC. impairment of long-lived assets held-for-use for the quarter ending 2013-09-30 was $0.00.
- BIOGEN INC. impairment of long-lived assets held-for-use for the quarter ending 2013-06-30 was $0.00.
- BIOGEN INC. impairment of long-lived assets held-for-use for the quarter ending 2013-03-31 was $0.00.
- BIOGEN INC. impairment of long-lived assets held-for-use for the quarter ending 2012-12-31 was $0.00.
- BIOGEN INC. impairment of long-lived assets held-for-use for fiscal 2012 was $0.00.
- BIOGEN INC. impairment of long-lived assets held-for-use for fiscal 2011 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2013-09-30 | $0.00 10-Q · filed 2013-10-28 | $0.00 derived: sum of 2 quarters · filed 2013-10-28 | $0.00 10-Q · filed 2013-10-28 | $0.00 derived: sum of 4 quarters · filed 2013-10-28 |
| 2013-06-30 | $0.00 10-Q · filed 2013-07-25 | $0.00 10-Q · filed 2013-07-25 | $0.00 derived: sum of 3 quarters · filed 2013-07-25 | |
| 2013-03-31 | $0.00 10-Q · filed 2013-04-25 | $0.00 derived: sum of 2 quarters · filed 2013-04-25 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $0.00 10-K · filed 2013-02-05 | ||
| 2012-09-30 | $0.00 10-Q · filed 2012-10-25 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |